Yaccarino, one of Elon Musk's top deputies, stepped down from her role at the social media site in July
Medical inflation forces Niva Bupa to revise pricing; expects 25% growth in FY26
With a federated architecture, no health records will be stored in a central repository, reducing the risk of a single hacked server leading to leakages
Fund II will invest and back about eight to 10 new companies over the next four years
Angel One and LivWell announce a joint venture to set up a digital-first life insurance firm in India with Rs 4 bn capital, aiming to improve access and affordability
Under the agreement, Fortis will manage operations of six Gleneagles hospitals and one clinic, earning a monthly fee and expanding its bed capacity and national presence
Chennai-based Aarthi Scans plans to add 65 new centres by 2030, with 90% in North India, while exploring fitness diagnostics and targeting a Rs 600 crore turnover
Tricog Health and Omron aim to screen 100 million patients for cardiac health by 2030 with KeeboHealth, an AI-powered connected health platform integrating remote monitoring & real-time data analytics
Shares of Kerala Ayurveda zoomed 20% to ₹511.70 on the BSE in Monday's intra-day trade with 2.87 million shares representing 23.9% of total equity changing hands till 1:11 PM.
Inventurus Knowledge Solutions shares fell after a 1.5% stake changed hands in a block deal; buyer and seller unknown
India's healthcare sector is on the cusp of significant transformation, driven by increased public and private investments, policy initiatives, and demographic shifts, believe analysts.
Global drugmakers, including generic drug manufacturers in India, are racing to develop their versions of blockbuster injectable obesity drugs from Denmark's Novo Nordisk and U.S.-based Eli Lilly
Indegene shares fell after 12 per cent equity, changed hands in two block trades
Zydus Lifesciences will acquire two US biologics manufacturing facilities from Agenus for up to $125 million, gaining immediate manufacturing capabilities and expanding its global presence
Apollo anticipates a 140 basis points hit to operating profit margins in FY26 due to new hospitals
Without urgent boosts in investment, experts warn India will struggle to meet both everyday and emergency health demands
Singapore-based company says it has largest dedicated healthcare PE fund for South and Southeast Asia
Focus on growth segments and capacity expansion boosted CKA Birla Group company BirlaNu's volumes in the March quarter and FY2024-25, according to Managing Director and CEO Akshat Seth. BirlaNu reported an 80 per cent surge in volumes for the March quarter, with pipes and construction chemicals driving the momentum, Seth said. Full fiscal year saw a 57 per cent increase in revenue and a 76 per cent rise in volumes, he added. The construction chemicals and pipes manufacturer doubled its AAC block capacity in Chennai to 4 lakh cubic meters per year and launched Parador in India, marking its entry into the home and interior space, Seth said. The company also introduced organic-based stabilisers (OBS) in uPVC pipes, eliminating heavy metals and setting new benchmarks for health and sustainability in potable water solutions. "The transition to OBS technology in our uPVC pipes reflects our focus on reducing environmental impact while delivering the highest quality to our customers," said
India's orthopaedic and cardiac implant sector is expected to reach USD 4.5-5 billion by 2027-28, mainly driven by strong domestic demand and gradually growing exports, a report said on Monday. Currently, the orthopaedic and cardiac implant sector, including exports, stood at USD 2.4-2.7 billion in FY24, according to a report by CareEdge Ratings. The growth in the sector is led by increasing per capita income, greater healthcare awareness, ageing population, expanding healthcare infrastructure, and broadening insurance coverage, it stated. The report said that domestic manufacturers have grown at a faster pace than the dominant foreign MNCs in recent years, aided by their price competitiveness and a gradual build-up of an efficacy and safety track record. The segment is dominated by the presence of foreign multinational companies, which largely import the implants and sell them in India as the implant business requires strong technological capabilities, a proven track record of saf
Healthtech firm Pristyn Care moves from asset-light model to hospital ownership, aiming for 50 hospitals, Rs 2,000 crore revenue and 20% Ebitda by FY28 IPO